The District of Columbia Clinical Trials Unit (DC CTU)

项目摘要 哥伦比亚特区临床试验单位(DC CTU)将对患有和面临癌症风险的人进行临床试验 哥伦比亚特区的艾滋病毒，那里1.8%的总人口和2.7%的非裔美国人与艾滋病毒一起生活 爱滋病毒。DC CTU将联合两个现有的、高性能的DAIDS/NIAID临床研究网站(CRS)， 惠特曼-沃克健康CRS和乔治华盛顿大学CRS在一个新的CTU中，参与了 艾滋病毒/艾滋病成人治疗和艾滋病毒预防临床试验网络。我们的创新和地理位置- 专注的DC CTU将确保模范临床试验的管理、招募和保留多样化 参与者样本，社区参与战略建立在现有伙伴关系和良好的 参与性做法。DC CTU将实现四个具体目标：1)提供科学领导和 行政基础设施，以便在两个月内高质量地进行治疗和预防研究 建立CRSS；2)实施最佳做法，以确保招聘和保留率持续居高不下； 参与者安全；以及实验室、药房、数据和监管方面的卓越表现；3)积极与当地 社区以确保诊所内外不同参与者的最佳登记，使用 良好的参与性做法；以及4)利用从DC CFAR和DC队列获得的资源 聘请高级研究人员、指导研究人员进行临床试验，并访问广泛的 为解决国家卫生研究院以及网络科学和方案优先事项提供的服务。华盛顿的反恐小组将与 参与者可以从创新的临床试验中受益，同时我们为高质量的参与性试验做出贡献 最终将结束艾滋病毒流行的研究。

Project Summary The District of Columbia Clinical Trials Unit (DC CTU) will conduct clinical trials for persons with and at risk for HIV in DC, where 1.8% of the overall population and 2.7% of the African-American population are living with HIV. The DC CTU will unite two existing, high-performing DAIDS/NIAID Clinical Research Sites (CRS), the Whitman-Walker Health CRS and the George Washington University CRS, in a new CTU, participating in the HIV/AIDS Adult Therapeutics and HIV Prevention Clinical Trials Networks. Our innovative and geographically- focused DC CTU will ensure exemplary clinical trials management, recruitment, and retention of a diverse sample of participants, with a community engagement strategy built on existing partnerships and Good Participatory Practices. The DC CTU will achieve four specific aims: 1) Provide scientific leadership and administrative infrastructure to allow high-quality conduct of therapeutic and prevention studies at two established CRSs; 2) Implement best practices to ensure continued high recruitment and retention rates; participant safety; and laboratory, pharmacy, data, and regulatory excellence; 3) Actively engage with the local community to ensure optimal enrollment of diverse participants from within and beyond clinic settings using Good Participatory Practices; and 4) Capitalize on the resources available from the DC CFAR and DC Cohort to engage senior investigators, mentor investigators in clinical trials conduct, and access a broad array of services to address NIH and network scientific and programmatic priorities. The DC CTU will engage participants who can benefit from innovative clinical trials while we contribute to high-quality participatory research that will eventually end the HIV epidemic.